Trial Profile

A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMCnyeso (Primary)
Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Synovial sarcoma; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms ImmTAC
Sponsors Immunocore

02 Jul 2021 Status changed from active, no longer recruiting to discontinued.
12 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
12 Apr 2021 Planned primary completion date changed from 1 Mar 2021 to 1 May 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com